Alpha -Tocopherol Dl- Ergocalciferol Phytonadione
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Alpha -Tocopherol Dl- Ergocalciferol Phytonadione
- Fat-Soluble Vitamins (A/D/E/K): No Repurposing Candidates Identified
Fat-Soluble Vitamins (A/D/E/K): No Repurposing Candidates Identified
One-Sentence Summary
This entry represents a combination of four fat-soluble vitamins — DL-alpha-tocopherol (Vitamin E), ergocalciferol (Vitamin D2), phytonadione (Vitamin K1), and Vitamin A palmitate — typically co-administered in patients with fat malabsorption disorders. The TxGNN model did not generate any repurposing predictions for this combination, most likely due to the absence of a DrugBank identifier and the multi-ingredient nature of the query string. No clinical trial or literature evidence is available within this evaluation package, and the recommended action is Hold pending data remediation.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (no regulatory records found) |
| Predicted New Indication | None identified |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A — no predictions generated |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
No TxGNN repurposing predictions were generated for this entry. The most probable cause is that the query string consists of four distinct active ingredients separated by semicolons, with no associated DrugBank ID — preventing the system from mapping any single node in the knowledge graph.
Each component has a well-characterised physiological role: Vitamin A palmitate supports epithelial integrity, immune defence, and vision; ergocalciferol (Vitamin D2) regulates calcium/phosphate homeostasis and modulates innate immunity; DL-alpha-tocopherol (Vitamin E) functions as a lipid-soluble antioxidant protecting cell membranes from oxidative damage; and phytonadione (Vitamin K1) is an essential cofactor in the coagulation cascade (γ-carboxylation of clotting factors II, VII, IX, X). Together, this “ADEK” combination is a recognised clinical protocol for patients with chronic fat malabsorption (e.g., cystic fibrosis, cholestatic liver disease, short bowel syndrome).
Without a unified DrugBank identifier or TxGNN graph embedding, a formal mechanism-based repurposing analysis cannot be conducted at this stage.
US Market Information
No US NDA records were found for this specific four-component combination formulation.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN pipeline produced zero predictions for this entry due to missing DrugBank mapping and the multi-ingredient query format; there is no evidence base on which to make a repurposing judgment.
To proceed, the following is needed:
- Resolve DrugBank IDs — query each component individually (DL-alpha-tocopherol, ergocalciferol, phytonadione, Vitamin A palmitate) to obtain graph-compatible identifiers
- Re-run TxGNN prediction — either per-component or by mapping the combination to a representative canonical entry
- Obtain MOA data — call DrugBank API for each ingredient to populate mechanism-of-action fields (currently listed as Data Gap DG002)
- Download package insert — retrieve the TFDA/FDA labelling PDF to resolve safety warnings and contraindications (Data Gap DG001)
- Clarify product scope — determine whether this combination exists as a single licensed product or as individually co-prescribed ingredients, as this affects regulatory pathway analysis
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.